( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Jazz Pharmaceuticals plc

09 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


07 Nov, 2017, 21:05 GMT Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Total Revenues Increased 10% to $412 Million Launched Vyxeos in the U.S. in August 2017 Vyxeos EU Marketing Authorization Application Submission...


03 Nov, 2017, 12:30 GMT Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Vyxeos granted accelerated assessment review status from European Medicines Agency's Committee for Medicinal Products for Human Use Jazz...


01 Nov, 2017, 13:29 GMT Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting

Nineteen abstracts accepted for three Jazz hematology/oncology products Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that thirteen...


24 Oct, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017,...


12 Sep, 2017, 13:30 BST Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for...


01 Sep, 2017, 17:45 BST Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that the initial purchasers of the recently announced private...


30 Aug, 2017, 21:05 BST Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Wells Fargo...


29 Aug, 2017, 11:30 BST Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products

Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75...


18 Aug, 2017, 12:00 BST Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced an offering by Jazz Investments I Limited, its wholly-owned...


17 Aug, 2017, 21:13 BST Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of...


08 Aug, 2017, 21:05 BST Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results

Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with...


03 Aug, 2017, 15:15 BST Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m....


26 Jul, 2017, 21:05 BST Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH ("XLp") for the rights to...


24 Jul, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017,...


06 Jun, 2017, 22:05 BST Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year Jazz...


06 Jun, 2017, 22:01 BST Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year Jazz...


31 May, 2017, 21:05 BST Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority...


24 May, 2017, 21:07 BST Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem®...


24 May, 2017, 21:05 BST Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting

Twelve Jazz-Sponsored Oral and Poster Presentations To Be Presented Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that twelve...


16 May, 2017, 21:05 BST Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


09 May, 2017, 21:05 BST Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results

Total Revenues Increased 12% to $376 Million Settled Xyrem Patent Litigation with First ANDA Filer Completed Rolling NDA Submission for Vyxeos...


26 Apr, 2017, 21:05 BST Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Abstract Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017 Jazz...


25 Apr, 2017, 21:05 BST Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after...